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access and uptake of novel oncology drugs in the Slovak repub-
lic over a 7 year period based on sales data provided by IMS
Health. Slovakia has a national public oncology register, which
collects incidence, mortality and stage of diagnosis on all cancer
types. We linked the national cancer epidemiological data to
the cancer drug list and to the sales for cancer drugs. We per-
formed analysis of the possible effect of novel cancer drug
introduction and consumption on cancer survival and mortal-
ity. RESULTS: Oncological disease mortality in Slovakia had an
increasing trend on a long-term basis, from 1999–2000 the
mortality has decreased. Incidence and prevalence (in accor-
dance with the world trends) increases. According to IMS and
OECD health data the market for L01 and L02 drugs was
€53,593 000, this represents €10 per inhabitant. Expenditures
in L01 + L02 accounts for 8,9% of the Rx expenditures or
7,9% of Total Pharma Market. CONCLUSIONS: Patient
access to new cancer drugs in Slovakia improved signiﬁcantly in
the last years. It is highly probable that the improving survival
is related to the use of modern surgical and diagnostic methods,
earlier diagnostics of oncological diseases and better availability
of innovative drugs.
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OBJECTIVES: Public health approaches for prevention are con-
sidered to be successful with climbs in the numbers of services
rendered. However, more thorough evaluations are required to
uncover the still unmet need that remains hidden and harder to
reach. The objective of this study is to estimate the impact of
physician supply, mammography facilities, and managed care
penetration on use of mammography screening. METHODS:
Retrospective self-reported cross-sectional data from Behavioral
Risk Factor Surveillance System for years 2000, 2002, and 2004
along with county level supply variables from area resource ﬁle,
were used in the analysis. The analysis was restricted to females
between 40–69 years of age. We estimate a series of multivariate
regression model to assess the effect of individual and contextual
supply variables on mammography screening. We also use varia-
tion in the physician supply, managed care penetration at the
county level over the 5-year period to estimate its impact on
mammography screening using a ﬁxed effect estimation
approach. RESULTS: Women living in rural areas were less likely
(Coefﬁcient = -0.023, 95% CI = -0.031–0.014) to obtain a
mammogram even after controlling for supply side variable .
Among the supply side variables only managed care penetration
signiﬁcantly predicted mammography screening. In areas with
higher managed care penetration, women were more likely to get
screened. CONCLUSIONS: Insurance status was one of the
major determinants of mammography screening for females
residing in rural areas. Contextual supply variables had lesser
impact on mammography screening compared to individual level
characteristics.
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OBJECTIVES: To evaluatie simultaneously frequency of occur-
rence, outcomes, and cost of care of renal cell carcinoma (RCC),
in order to provide empiric evidence on the burden of RCC.
METHODS: Retrospective, naturalistic longitudinal study based
on claims of individuals enrolled in the Friuli Venezia Giulia
(FVG) administrative database. Since 1980, all FVG inhabitants
are registered in an administrative database which includes infor-
mation on hospital admissions, outpatients care, pharmaceutical
prescriptions and mortality. We selected residents of FVG who
had a RCC ﬁrst hospital admission (ICD9 code 189) during the
period 2000–2004, and we followed them up until: June 30,
2005, death or transfers. Direct medical costs (hospitalizations,
drugs, visits, diagnostics and laboratory exams) were quantiﬁed
using prices or tariffs expressed in Euro 2005. The perspective of
FVG Regional Health Service was adopted. Survival and costs
analysis were performed considering the presence or the absence
of metastases. RESULTS: We enrolled 1358 patients (63% male),
the 18.8% representing a metastatic-stage, leading to a crude
incidence of 23/100,000 person-years. During follow-up, 76% of
the metastatic patients and 21% of the non metastatic patients
died. The risk of death was signiﬁcantly higher among metastatic
stage patients with a median survival of about six months. The
cost per patient related to the ﬁrst year after diagnosis for sub-
jects with and without metastases was €13,692 and 10,502 Euro,
respectively, with a mean difference of 3,363 Euro after adjusting
for age and sex. Total health care costs per-patient over the
maximum of follow-up were €16,090 for the localized-stage
group and €17,656 in the metastatic-stage group. CONCLU-
SIONS: Results from our study show that, due to the large
number of hospitalizations and the high mortality, the epidemio-
logic and socioeconomic burden to the health care system and to
the society of RCC is high.
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OBJECTIVES: In order for a new pharmaceutical treatment to
demonstrate cost-effectiveness, it is important to understand the
current standard clinical management practices for the relevant
patient population. In some therapeutic areas, this information
can be readily gleaned from clinical practice guidelines, data-
base analyses and clinical input. However, in more complex
conditions, standard practices are undeﬁned and vary markedly
both within and between countries. In such circumstances,
valuable information can be obtained by conducting a chart
audit. We report on the different approaches and requirements
for conducting chart audits in Australian hospitals.
METHODS: In total, 79 potential investigators were invited to
participate in two separate studies. Investigators were contacted
up to four times to maximise response. 52 investigators
responded and 12 agreed to participate. Two investigators
agreed to participate in both studies. RESULTS: All sites
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